KLK4 and hereditary angioedema: The current pharmacologic therapies for acute attacks of HAE include C1-INH replacement (plasma-derived or recombinant), ecallatide (a kallikrein inhibitor), and icatibant (a bradykinin receptor antagonist) [37,38,39,40].